| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8272499 | Journal of the Neurological Sciences | 2018 | 6 Pages |
Abstract
None of the measured biomarkers were associated with the neurological outcome evaluated at six months after aSAH. Elevated levels of S100B in patients with non-severe initial presentation suggest an adaptive role of this biomarker in aSAH. Based on our findings it is not advisable to use these biomarkers to guide clinical decision-making in patients with aSAH.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Heikki Kiiski, Jaakko LÃ¥ngsjö, Jyrki Tenhunen, Marika Ala-Peijari, Heini Huhtala, Mari Hämäläinen, Eeva Moilanen, Jukka Peltola,